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The compound genotype KIR3DS1/HLA-B Bw4-80I, which presumably favors natural killer cell activation, has been
implicated in protection against HIV disease. We show that this genotype confers dual protection over the course of
HIV disease; early direct containment of HIV viral load, and late specific defense against opportunistic infections, but
not AIDS-related malignancies. The double protection of KIR3DS1/Bw4-80I in an etiologically complex disease such as
AIDS, along with the disease specificity of its effects is conceptually novel and underscores the intricacy of host
immunogenetics against HIV/AIDS.
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Introduction
Natural killer (NK) cells are central components of the
innate immune response, providing early defense against
viral infections and tumor cells by production of cytokines
and direct cytotoxicity [1,2]. Regulation of their activity is
under the control of a range of activating and inhibitory
receptors that work in concert to identify and destroy
aberrant target cells, while recognizing and sparing unble-
mished self [3,4]. The group of killer immunoglobulin-like
receptors (KIR) on NK cells, which contains allotypes that are
either activating or inhibitory, participate in the complex
regulation of NK cell responses through recognition of
speciﬁc human leukocyte antigen (HLA) class I molecules on
target cells [3]. KIR and HLA loci are both highly poly-
morphic and they map to distinct human chromosomes
(Chromosomes 19 and 6, respectively), and therefore, they
segregate independently. Both the KIR receptor and its
speciﬁc HLA ligand must be present in order to regulate NK
cell activity, such that one without the other is functionally
inert. The speciﬁc combination of the activating KIR allele
KIR3DS1 with HLA-B alleles that encode molecules having
isoleucine at position 80 (HLA-B Bw4-80I) was previously
observed to exert a protective effect against AIDS progres-
sion after HIV infection based upon a genetic association
analysis of AIDS cohorts [5]. We proposed that KIR3DS1
might bind HLA-B Bw4-80I allotypes on target cells, thereby
signaling the NK cell to kill the HIV infected target, although
direct evidence for a KIR3DS1: HLA-B Bw4-80I interaction
has not been reported. The synergistic protection of
KIR3DS1 þ HLA-B Bw4-80I (termed ‘‘KIR3DS1/Bw4-80I’’
hereafter) was observed against progression to CD4 T cell
depletion and development of AIDS-deﬁning illnesses col-
lectively. Thus, KIR3DS1/Bw4-80I may confer protection
against HIV directly by killing HIV-infected target cells,
and/or indirectly by preventing/delaying onset of speciﬁc
AIDS-deﬁning illnesses.
Results/Discussion
AIDS-deﬁning illnesses include two basic types of diseases,
opportunistic infections and certain malignancies. Given the
protective effect of KIR3DS1/Bw4-80I on progression to CD4
T cell decline and AIDS in general, we tested the speciﬁcity of
this genotype in defense against individual AIDS-deﬁning
illnesses and against HIV directly. The most common AIDS
outcomes in our cohorts include two malignancies, Kaposi
sarcoma (KS) and AIDS lymphoma, and three diseases caused
by opportunistic infections (OI): pneumocystis carinii pneu-
monia (PCP), cytomegalovirus retinitis (CMVR), and myco-
bacterium avium complex (MAC). The other OI observed in
our cohort of patients were grouped together in this study
because their individual frequencies were too low to consider
individually (termed ‘‘other OI’’; see Table 1 footnote). The
combined group of all OI and combined AIDS-related
malignancies occurred at similarly advanced stages of HIV-
related immune suppression (mean time to CD4 ,200: 5.8 vs.
6.5 y; p .0.1).
Disease-free survival and categorical analyses were per-
formed on a group of 1,184 study participants whose date of
HIV seroconversion was known within a 6-mo period on
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average (seroconverters). All clinical data used in this study
was collected before the advent of highly active antiretroviral
therapy (HAART) in order to avoid confounding of our
results by efﬁcacious antiretroviral therapy. In categorical
analyses, the frequency of KIR3DS1/Bw4-80I in each of six
individual disease groups (KS, lymphoma, PCP, CMVR, MAC,
other OI) and combinations of these groups (malignancies
combined and all OI combined) were compared to the
frequency of this compound genotype in a control group of
88 HIVþ long-term nonprogressors (LTNP) who had partici-
pated in their respective studies for at least 15 y and had
never presented with disease symptoms. Since the control
group was consistent for all categorical analyses, effects of
KIR3DS1/Bw4-80I across distinct disease outcomes could be
compared directly. In the primary analysis, individuals were
included in a disease group only if that disease was the ﬁrst
AIDS outcome diagnosed since HIV seroconversion, regard-
less of subsequent diagnoses (termed ‘‘1st outcome only’’).
This analysis eliminates confounding by the possibility that
developing an initial disease may increase the risk of
developing a second one. In the secondary analysis, individ-
uals were included in a disease group if they had ever
developed the disease (‘‘anytime outcome’’), regardless of
whether it was the ﬁrst or a subsequent disease diagnosis
(thus, a single individual may be counted in multiple disease
groups). This analysis is less rigorous than the ﬁrst, but
involves more events and was used to support or refute the
primary analysis.
Of the six individual disease groups, signiﬁcant (p ,0.05)
KIR3DS1/Bw4-80I protection against PCP, other OI, and MAC
was observed in analyses considering 1st outcome only,
anytime outcome, or both (Table 1). Notably, there was no
signiﬁcant effect of this genotype against KS or AIDS
lymphoma. These data indicated that KIR3DS1/Bw4-80I
confers defense against opportunistic infections, but not
against AIDS malignancies in general. Substantiating these
ﬁndings, KIR3DS1/Bw4-80I was associated with strong pro-
tection against all OI outcomes combined (OR¼ 0.36–0.4, p¼
0.003–0.005), but not against the combined AIDS malignan-
cies (OR¼0.75–1.0, p¼0.5–0.9). Similar results were observed
after increasing the control group from 88 to a total of 197
LTNP by the addition of 109 seroprevalent LTNP (those
patients who were HIVþ at study entry, and remained free of
AIDS for at least 13 y following entry into the study; for OI,
OR¼ 0.4, p¼ 0.001; for malignancies, OR¼ 1.1, p¼ 0.8). The
apparent lack of KIR3DS1/Bw4-80I protection against CMV
retinitis, the only OI tested individually for which KIR3DS1/
Bw4-80I showed no signiﬁcant effect, could have to do with
the immune privileged status of the retina where NK cell
accessibility may be restricted regardless of the receptors they
express. Indeed, there is little or no inﬁltration of inﬂamma-
tory cells into the retina in association with CMV retinits [6].
The Bw4-80I group includes two alleles, B*57 and B*27,
that are known to be highly protective in the acquired
immune response against HIV based on both functional and
genetic epidemiological data [7]. In contrast, B*35-Px
associates with rapid progression to AIDS [7,8] and carries
the Bw6 motif (i.e. not Bw4-80I). These three alleles show the
Table 1. Effect of KIR3DS1/Bw4-80I across Distinct Disease Outcomes in HIV-1 Infection
Disease Categorical Analysisa Survival Analysis
First Outcome Only Anytime Outcome First Outcome Anytime Outcome
n OR p-Value N OR p-Value n RH p-Value n RH p-Value
Kaposi sarcoma 52 0.75 0.6 81 0.60 0.2 54 1.13 0.8 81 0.92 0.8
Lymphoma 15 2.1 0.2 30 1.5 0.4 17 2.56 0.08 29 1.93 0.1
Total malignancy 67 1.0 0.9 105 0.75 0.5 71 1.42 0.3 104 1.08 0.8
PCP 132 0.38 0.02 180 0.52 0.07 133 0.59 0.1 180 0.81 0.4
CMV retinitis 41 0.58 0.3 95 0.60 0.2 43 1.03 0.9 94 0.94 0.8
MAC 27 0.33 0.2 64 0.20 0.01 27 0.52 0.4 64 0.32 0.05
Other OI 152 0.33 0.007 211 0.39 0.01 154 0.45 0.01 210 0.58 0.03
Total OI 338 0.36 0.003 374 0.40 0.005 342 0.56 0.004 373 0.61 0.008
Bolded p-values are 0.05.
aThe frequency of KIR3DS1/Bw4-80I in each disease group listed was compared to that in a control group of long term non-progressors (LTNP; seroconverters who have been in the study
for 15 y and have remained disease-free; n¼ 88), and odds ratios and p-values were determined. Statistics for the unadjusted model are shown.
n, number of patients with the disease listed in column 1; OR, odds ratio; PCP, pneumocystis carinii pneumonia; CMV, cytomegalovirus; MAC, mycobacterium avium complex; OI,
opportunistic infection (other OI includes candidiasis, cryptococcosis, coccidioidomycosis, histoplasmosis, cryptosporidiosis, isosporiasis, toxoplasmosis, herpes simplex, progressive
multifocal leukoencephalopathy, various bacterial infections).
DOI: 10.1371/journal.ppat.0020079.t001
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Synopsis
Natural killer (NK) cells are part of the innate immune response
which provides the first line of defense against viral infections such
as HIV by production of cytokines and direct killing of infected cells.
NK cells possess a variety of inhibitory and activating receptors that
upon binding to their HLA class I ligands on target cells, regulate
activation and inhibition of NK cell responses. A protective effect of
the specific combination of the activating receptor KIR3DS1 with
HLA-Bw4 alleles that have isoleucine at position 80 (HLA-B Bw4-80I)
against AIDS progression was reported previously. Based on this
genetic association, KIR3DS1 on NK cells was proposed to bind to
HLA-B Bw4-80I on HIV-1 infected target cells, thereby signaling the
NK cell to kill the target. Here we present data showing that this
compound genotype also confers protection against the develop-
ment of AIDS defining opportunistic infections. Interestingly, no
protection against the development of AIDS defining malignancies
was observed. The double protection of this compound genotype in
AIDS, along with the specificity of its effects is a novel finding and
underscores the complex role of host immunogenetics against HIV/
AIDS.
strongest effects on progression to AIDS relative to all other
individual HLA alleles in analyses of the cohorts used herein
[7,9]. Thus, KIR3DS1/Bw4-80I protection could be artiﬁcially
strengthened by the presence of the protective B*57 and
B*27 in the Bw4-80I group and the absence of the susceptible
B*35-Px from this group. However, removing patients with
these alleles (n ¼ 345) from the analysis did not alter the
strength of KIR3DS1/Bw4-80I protection against OI (OR ¼
0.35, p ¼ 0.019), indicating that the protection conferred by
KIR3DS1/Bw4-80I is separate from the individual effects of
these three alleles on the acquired immune response. Further,
in a model adjusting for the effects of these three alleles as
well as time to CD4 ,200, the strength and signiﬁcance of the
KIR3DS1/Bw4-80I protection remained (OR ¼ 0.34, p ¼ 0.03).
The lack of an effect of KIR3DS1/Bw4-80I on AIDS malig-
nancy was not altered by removing or adjusting for these
same variables.
The categorical analyses indicated that KIR3DS1/Bw4-80I
protects against ever developing an OI, but not AIDS
malignancy after HIV infection. Some patients with
KIR3DS1/Bw4-80I do, however, develop OI even as a ﬁrst
AIDS outcome. We therefore tested whether KIR3DS1/Bw4-
80I delayed progression to OI as a ﬁrst AIDS outcome using
1,126 seroconverters in survival analysis (i.e. time since
seroconversion to the ﬁrst AIDS outcome diagnosed; Figure
1, Table 1). KIR3DS1/Bw4-80I was shown to delay progression
to OI as a ﬁrst outcome only [unadjusted: Relative Hazard
(RH) ¼ 0.56, p ¼ 0.004; adjusted for time to CD4 ,200 as a
time-dependent covariate and HLA-B*57, -B*27, and -B*35-Px
as ﬁxed covariates in a Cox proportional hazards model: RH¼
0.58, p ¼ 0.007]. Further, delayed progression to OI was
observed regardless of whether it was the ﬁrst or a subsequent
AIDS diagnosis (unadjusted: RH ¼ 0.61, p ¼ 0.008; adjusted:
RH ¼ 0.64, p ¼ 0.016; unpublished data). This genotype
showed no protection in survival analysis against progression
to AIDS malignancy, whether it was the ﬁrst outcome only or
not (RH¼ 1.1–1.4, p¼ 0.3–0.8). Adjusting for race in the Cox
model did not affect the results (RH ¼ 1.34, p ¼ 0.34 for
malignancy; RH¼ 0.56, p¼ 0.004 for OI), which concurs with
our previously observed effect of this compound genotype on
AIDS progression in both European and African Americans
[5]. Thus, the survival analysis conﬁrmed and extended the
observations of the categorical analyses with regard to both
OI and AIDS malignancies.
These data raised the possibility that the protective effect
of KIR3DS1/Bw4-80I on AIDS progression that was reported
previously may be completely due to protection against OI,
rather than HIV directly. Viral load set point measurements
(the mean of all viral load measurements determined between
6 mo to 3 y after infection) were available for 391 European
American seroconverters from the MACS. The mean (natural
log) viral load set point for patients with KIR3DS1/Bw4-80I (n
¼ 47, mean ¼ 9.4) was signiﬁcantly lower than that for
individuals without this genotype (n ¼ 344, mean ¼ 10.1; p ¼
0.01; Table 2), supporting a direct protective effect of
KIR3DS1/Bw4-80I against HIV replication early after infec-
tion, and well before the development of AIDS-deﬁning
illnesses in all of the 391 patients studied here. This
difference in viral load set points between the KIR3DS1/
Bw4-80I positive vs. negative groups is likely to have clinical
signiﬁcance based on the correlation between viral load set
point levels and time to AIDS that has been reported
previously [10].
These data indicate pleiotropic protective effects of
KIR3DS1/Bw4-80I over the course of HIV disease, including
relatively early control of viral load after infection and
subsequently against developing OI (Figure 2). While these
two protective effects are not completely independent of one
another, adjusting for time to CD4 ,200, a measurement
linked to viral load set point [10], did not alter the protection
Figure 1. Effect of KIR3DS1/Bw4-80I on Progression to AIDS-Defining Illness
Kaplan-Meier survival analyses illustrating the effect of KIR3DS1/Bw4-80I on progression to A) AIDS-defining opportunistic infections and B) AIDS-
defining malignancies among seroconverters. Patients with KIR3DS1/Bw4-80I (red curve) were compared with patients missing this genotype (blue
curve). RH and p-values from corresponding Cox models are given.
DOI: 10.1371/journal.ppat.0020079.g001
Table 2. Summary of Mean HIV-1 RNA Load among 391
Seroconverters during the First 3 y after Seroconversion
Group n Mean VL SD Ln Mean VLa SD
All 391 75,711 128,005 10.0 1.56
3DS1/Bw4-80Iþ 47 56,155 97,816 9.4 1.84
Others 344 78,382 131,483 10.1 1.51
ap-Value¼ 0.01 for difference in Ln mean VL between 3DS1/Bw4-80Iþ versus others.
n, number of individuals; VL, viral load (copies/ml); SD, standard deviation.
DOI: 10.1371/journal.ppat.0020079.t002
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conferred by KIR3DS1/Bw4-80I against OI. Notably, this
genotype does not protect against AIDS malignancy. The
conserved, activating NK cell receptor NKG2D has been
implicated in surveillance against and elimination of tumor
cells [11] and this receptor may also play a role in control of
AIDS malignancies, beyond that of any activating KIR. To
date, only a single genetic epidemiological study has
implicated an activating KIR in tumor pathogenesis [12]. In
this case, KIR3DS1 was associated with increased risk of
cervical neoplasia, possibly due to enhancement of chronic
inﬂammation of the cervix, a likely precursor of cervical
neoplasia [13]. Thus, environmental factors, variation in the
HIV genome, or host genetic variants other than KIR3DS1/
Bw4-80I may determine the risk of developing AIDS
malignancies.
It is not clear whether the protective effect of KIR3DS1/
Bw4-80I is mediated through NK cells, CD8þ T cells, or both.
NK cell activation through KIR3DS1 binding to ligand on
HIV infected target cells may confer rapid protection against
the virus very soon after infection and before the acquired
immune response ensues. This does not preclude the
possibility of KIR3DS1-mediated NK and/or T cell responses
during chronic infection, however, and indeed the data
presented here indicates protection against OI during the
chronic phase of HIV infection. Functional studies will be
necessary to deﬁne the stage(s) and effector cell type(s)
responsible for the association of KIR3DS1/Bw4-80I with
protection against AIDS that has been described previously
[5] and herein.
The HLA class I loci show the strongest and most consistent
effects (across studies) on HIV disease relative to any other
single genetic locus. Of the three HLA class I loci, HLA-B is
the most rapidly evolving [14] and it also appears to be the
most consequential in the acquired immune response against
HIV from both functional and genetic epidemiological
perspectives [9,15]. On a population level, control of a
rapidly evolving pathogen such as HIV likely requires host
genetic factors that are highly polymorphic and evolving
rapidly themselves, characteristics of both the HLA class I and
KIR loci [9,15,16]. Thus, it may not be coincidental that
allotypes of the HLA-B locus in combination with a KIR locus
would be central to the innate immune response against both
HIV and the opportunistic infections stemming from HIV-
mediated immune suppression. It is now clear that HLA class I
contributes heavily to both the acquired and the innate
immune responses, and decoding the complexity of its effects
in HIV disease may prove essential for conquering this virus.
Materials and Methods
Study participants. Individuals infected with HIV-1 for whom dates
of seroconversion were known were derived from four cohorts: the
Multicenter AIDS Cohort Study (MACS) [17], the Multicenter
Hemophilia Cohort Study (MHCS) [18], the San Francisco City Clinic
Cohort (SFCCC) [19] and the AIDS Linked to Intravenous Experience
(ALIVE) [20] (N¼1,184; European American¼799, African American
¼ 332, Other ¼ 53). There were several seroconverters for whom the
date (after seroconversion) of ﬁrst disease outcome was not known
with regard to OI (n ¼ 58) and malignancy (n ¼ 64). Thus, we were
unable to use these individuals in the survival analyses, but we were
able to use them in categorical analyses, which do not take time to
disease outcome after seroconversion into account. The categorical
analyses employed a control group of 88 HIVþ LTNPs who had
participated in their respective studies for at least 15 y and had never
presented with disease symptoms (79 European Americans, ﬁve
African Americans, ﬁve Other). Samples from long term non-
progressing seroprevalent individuals (individuals who entered the
study HIV positive, were followed for at least 13 y, and never
developed AIDS; n¼ 109) were used as additional controls in one set
of categorical analyses in order to boost the sample size in the control
group (99 European Americans, six African Americans, four Other).
European American seroconverters with known viral load set point
data were derived from the MACS (N¼ 391). This study was approved
by the Protocol Review Ofﬁce of the NCI institutional review board.
Informed consent was obtained at the study sites from all individuals.
HLA and KIR genotyping. Genotyping of the HLA and KIR loci
were performed as previously described [5].
Viral load set point measurements. Viral load measurements
determined previously from 391 European American seroconverters
were available for analysis from the MACS cohort. Prior to 1997, HIV-
1 RNA copies/mL was measured retrospectively on stored samples
using reverse-transcription polymerase chain reaction (Amplicor;
Roche Diagnostics, Nutley, New Jersey) with an assay quantiﬁcation
limit of 400 copies/mL [10]. Samples below the quantiﬁcation limit
were subsequently tested with the Roche Ultrasensitive Assay with an
assay detection limit of 50 copies/ml. Prospectively, HIV-1 RNA
copies/mL are measured initially with Roche Ultrasensitive Assay
whose detection limit is 50 copies/mL. All HIV RNA measurements
obtained during the ﬁrst 3 y after the ﬁrst HIV-seropositive visit were
used to calculate viral load set point values for each individual. Viral
load measurements were ﬁrst transformed to natural logarithm, and
then averaged to determine the mean viral load set point for each
individual. The average number of measurements per patient was 4.8
with a range of 1–10.
Statistical methods. Analyses were carried out on seroconverters
from all of the cohorts combined. Although our previous study of
HLA and KIR in these patients showed consistent effects in African
Americans and European Americans [5], we performed the Cox
model analysis adjusted and unadjusted for race. The two models
yielded virtually identical results. Data management and statistical
analyses were performed with SAS 9.1 (SAS Institute, Cary, North
Carolina). PROC LOGISTIC was used for categorical analyses and
PROC LIFETEST and PHREG were used for Kaplan-Meier and Cox
model analyses. Statistical signiﬁcance refers to two-sided p-values
,0.05.
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Figure 2. Bimodal Protection of KIR3DS1/HLA-B Bw4-80I in HIV-1 Infection
Flow chart illustrating the dual protection conferred by KIR3DS1/Bw4-80I
in the natural history of HIV-1 infection: early control of HIV-1 viral load,
and late specific defense against opportunistic infections. There is no
effect of this genotype on the development of AIDS-related malignan-
cies.
DOI: 10.1371/journal.ppat.0020079.g002
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